If you are attending the DIA Annual meeting in Boston later this month, we invite you to come and see Virtify at booth number 1647.
Not only will you have the opportunity to learn about our newly launched product for Clinical and Regulatory Content Management – Virtify SCM, but we will be making a five dollar contribution to the The One Fund Boston for each visitor to our booth.*
Virtify is proud to call Boston home. As part of our commitment to keeping Boston Strong, we are pleased to be able to support The One Fund Boston which will be used to assist those families of the victims who were killed and the victims who were most seriously affected as a result of the tragic events during the Boston Marathon on April 15, 2013 and related events on April 18th and April 19th.
You may also find it worthwhile to come by our booth to learn about our exciting new product, Virtify SCM. Virtify SCM represents a groundbreaking approach to providing the pharmaceutical industry with powerful capabilities for collaborative / structured authoring and reviewing, content re-use, and workflow and content life cycle management. It has significant benefits across the organization in reducing overall cycle times, improving compliance, increasing efficiency, enhancing quality and improving decision-making. And you can receive more information about it and receive a brief demo during your visit to our booth or download a detailed SCM fact sheet that is available on our website.
If you would like to schedule a private demo or won’t be making it to DIA, but would like to find out more about Virtify SCM, contact Virtify at [email protected], +1 (617) 301-8708.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.